{
  "source": "PA-Med-Nec-Veozah.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2312-3\nProgram Prior Authorization/Medical Necessity\nMedication Veozah™ (fezolinetant)\nP&T Approval Date 8/2023, 8/2024, 11/2024\nEffective Date 2/1/2025\n1. Background:\nVeozah (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of\nmoderate to severe vasomotor symptoms due to menopause.\nVeozah use has been associated with reports of hepatotoxicity in post marketing studies that\ngradually resolve after discontinuation of Veozah. Baseline hepatic laboratory tests should be\nevaluated prior to initiation of Veozah.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Veozah will be approved based on all of the following criteria:\na. Diagnosis of moderate to severe vasomotor symptoms due to menopause\n-AND-\nb. History of failure (after a 30-day trial), contraindication or intolerance to one of the\nfollowing:\n1) Hormonal therapy (e.g., estradiol, Premarin, Prempro)\n2) Non-hormonal therapy [e.g., clonidine, gabapentin, selective serotonin\ninhibitors (e.g., paroxetine), serotonin and norepinephrine reuptake inhibitors\n(e.g., venlafaxine)]\n-AND-\nc. Patient has received baseline hepatic laboratory tests to rule out the presence of\nunderlying liver disease\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Veozah will be approved based on both of the following criteria:\na. Documentation of positive clinical response to therapy (e.g., decrease in frequency\nand severity of vasomotor symptoms from baseline)\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n1\nb. Patient has received periodic evaluation of hepatic laboratory tests to rule out liver\ninjury associated with Veozah use\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithst",
    "ry requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n4. References:\n1. Veozah [package insert]. Northbrook, IL: Astellas US LLC. August 2024.\n2. Khan, SJ, Kapoor, E, Faubion, SS, Kling, JM. Vasomotor Symptoms During Menopause:\nA Practical Guide on Current Treatments and Future Perspectives. Int J Womens\nHealth.2023: 15: 273-87.\nProgram Prior Authorization/Medical Necessity - Veozah\nChange Control\n8/2023 New program.\n8/2024 Annual review. Updated references.\n11/2024 Added criteria for hepatic laboratory tests and updated references.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}